MENU
+Compare
IMAB
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$0.97
Change
-$0.00 (-0.00%)
Capitalization
79.06M

IMAB I-MAB Forecast, Technical & Fundamental Analysis

a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Industry Biotechnology
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for IMAB with price predictions
Feb 21, 2025

IMAB in downward trend: 10-day moving average moved below 50-day moving average on February 10, 2025

The 10-day moving average for IMAB crossed bearishly below the 50-day moving average on February 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for IMAB turned negative on January 30, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

IMAB moved below its 50-day moving average on February 03, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for IMAB entered a downward trend on February 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where IMAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on February 18, 2025. You may want to consider a long position or call options on IMAB as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMAB advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .

IMAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.363) is normal, around the industry mean (12.496). P/E Ratio (0.000) is within average values for comparable stocks, (84.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). IMAB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (24.213) is also within normal values, averaging (251.218).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

IMAB is expected to report earnings to rise 16.27% to -12 cents per share on November 29

I-MAB IMAB Stock Earnings Reports
Q3'23
Est.
$-0.13
Q3'24
Missed
by $0.04
Q2'24
Beat
by $0.22
Q1'24
Est.
$-0.22
Q4'23
Beat
by $0.36
The last earnings report on November 14 showed earnings per share of -10 cents, missing the estimate of -7 cents. With 229.09K shares outstanding, the current market capitalization sits at 79.06M.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
555 West Haiyang Road
Phone
+86 2160578000
Employees
318
Web
https://www.i-mabbiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VIPS14.730.20
+1.38%
Vipshop Holdings Limited
MCD304.811.76
+0.58%
McDonald's Corp
AMRX7.83-0.04
-0.51%
Amneal Pharmaceuticals
URG0.94-0.02
-1.58%
Ur-Energy
EPIX1.72-0.03
-1.71%
ESSA Pharma

IMAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IMAB has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IMAB jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
+0.34%
VCYT - IMAB
43%
Loosely correlated
-4.56%
CTMX - IMAB
32%
Poorly correlated
-4.42%
RAPT - IMAB
31%
Poorly correlated
-0.79%
ARRY - IMAB
31%
Poorly correlated
-4.49%
AXON - IMAB
29%
Poorly correlated
-5.28%
More